ANTXR1 Facilitates Tumor Growth in Glioma Via Deactivating MAPK Signaling Pathway

Aijun Liang,Chaoyang Zhou,Jianzhong Zhang,Jingxing Leng,Bin Xi,Bin Zhou,Yu Yang,Ronglan Zhu,Liangchen Zhong,Xingxing Jiang,Dengfeng Wan
DOI: https://doi.org/10.21203/rs.3.rs-126784/v1
2020-01-01
Abstract:Background: Gliomas are commonly known as primary brain tumors and associated with frequent recurrence and an unsatisfactory prognosis in despite of extensive research in the underlying molecular mechanisms. In this study, we aimed to examine the role of ANTXR1 in glioma tumorigenesis and explore its downstream regulatory mechanism. Methods: We detected overexpression of ANTXR1 in glioma cell lines (SHG-44 and U251) in comparison with those in normal brain tissues.Result: Glioma cell growth and migratory ability were dramatically impaired as a result of silencing ANTXR1 by shANTXR1 lentivirus. ANTXR1 blockade also accelerated cell apoptosis since ANTXR1 held back apoptosis via targeting G2 phrase during cell mitosis. In vivo xenograft models verified in vitro findings above that the solid tumors stripped from mice were much lighter and smaller after depletion of ANTXR1 than controls. We also mechanically probed the downstream pathways and disclosed that overexpression of ANTXR1 abrogated the levels of MAKP9 and apoptisis-related protein HTRA2, but augmenting CCND1 and CDK6 levels in glioma cells. Our findings allow us to demonstrate that ANTXR1 acts as a tumor promoter in glioma induction through attenuating MAPK9-mediated gene transcription and HTRA2-induced apoptisis but intensifying CCND1-mediated proliferation. Conclusion: Together, we declare that ANTXR1 plays an indispensable role in glioma tumorigenesis via deactivating MAPK signaling and apoptosis pathway but activating PI3K/AKT-mediated cell growth. Our study provide a valuable clue to targeting ANTXR1 as a molecular target and a promising anticancer agent in glioma clinical therapeutics.
What problem does this paper attempt to address?